Abstract
|
Down-Regulation of miR-186 Correlates with Poor Survival in de novo Acute Myeloid Leukemia
by Ting-juan Zhang, Yu-Xin Wang, Dong-qin Yang, Dong-ming Yao, Lei Yang, Jing-dong Zhou, Zhao-qun Deng, Xiang-mei Wen, Hong Guo, Ji-chun Ma, Jiang Lin, Jun Qian
|
|
|
Background: MicroRNA-186 (miR-186) plays an important role in the pathogenesis of several cancers. Our study was intended to investigate the expression status and the prognostic implication of miR-186 in acute myeloid leukemia (AML).
Methods: Real-time quantitative PCR was carried out in 112 de novo AML patients and 28 controls.
Results: The level of miR-186 expression in AML was significantly down-regulated compared to normal controls (p < 0.001). Patients with low miR-186 expression presented significantly older age than those with high miR-186 expression (p = 0.004). MiR-186high patients had a significantly higher frequency of CEBPA mutation than miR186low patients (20% and 4%, respectively, p = 0.022). In addition, miR-186low patients had a significantly lower complete remission (CR) rate (30% vs. 53%, respectively, p = 0.028) than miR-186high patients. Moreover, miR186low patients showed significantly shorter overall survival (OS) time than miR-186high patients in both whole AML and non-M3 patients (p = 0.023 and 0.026, respectively). Additionally, the adverse prognostic impact of miR186 down-regulation was also shown in both whole AML and non-M3 patients without CEBPA mutation (p = 0.017 and 0.023, respectively).
Conclusions: Our study suggests that miR-186 down-regulation is a frequent event and predicts poor prognosis in de novo AML patients.
DOI: 10.7754/Clin.Lab.2015.150606
|
